Concord Biotech Ltd. (CONCORDBIO) fundamentals
Concord Biotech Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as CONCORDBIO (ISIN INE338H01029). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Concord Biotech Ltd. does
Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.
Valuation and market data
| Last close | ₹1321.20 |
|---|---|
| Market capitalisation | ₹13,821 crore |
| Enterprise value | ₹13,860 crore |
| P/E (TTM) | 53.32 |
| Price to book | 6.86 |
| Price to sales (TTM) | 7.38 |
| Book value per share | ₹192.63 |
| Dividend yield | 57.15% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Aug 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,108 crore | ₹351 crore | ₹263 crore | 25.17 |
| Mar 2025 | ₹1,245 crore | ₹496 crore | ₹373 crore | 35.65 |
| Mar 2024 | ₹1,051 crore | ₹409 crore | ₹305 crore | 29.13 |
| Mar 2023 | ₹888 crore | ₹320 crore | ₹238 crore | 22.76 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 44.1% |
|---|---|
| Foreign institutions (FII) | 7.3% |
| Mutual funds | 5.8% |
| Other domestic institutions | 5.1% |
| Retail and others | 37.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.